Diffuse Cutaneous Systemic Sclerosis Clinical Trial
Official title:
A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
Verified date | June 2024 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary Objectives: 1. The primary efficacy objective is to assess the efficacy of 52 weeks of open-label treatment with HZN-825 in participants with diffuse cutaneous systemic sclerosis, as measured by change from both baselines in forced vital capacity percent (FVC %) predicted. 2. The primary safety objective is to examine the safety and tolerability of 52 weeks of open-label treatment with HZN-825, inclusive of, but not limited to, adverse events (AEs), serious AEs (SAEs) and the adverse event of special interest (AESI), from Day 1 to 4 weeks after last dose.
Status | Enrolling by invitation |
Enrollment | 246 |
Est. completion date | September 29, 2026 |
Est. primary completion date | September 29, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Key Inclusion Criteria: 1. Completed the double-blind Treatment Period (Week 52) in Trial HZNP-HZN-825-301; participants prematurely discontinued from trial drug in Trial HZNP-HZN-825-301 for reasons other than safety or toxicity can be included at the discretion of the Investigator after completing Trial HZNP-HZN-825-301 scheduled visits, including Week 52 assessments. Key Exclusion Criteria: 1. Anticipated use of another investigational agent for any condition during the course of the trial. 2. New diagnosis of malignant condition after enrolling in Trial HZNP-HZN-825-301 (except successfully treated basal/squamous cell carcinoma of the skin or cervical cancer in situ). 3. Women of childbearing potential (WOCBP) or male participants not agreeing to use highly effective method(s) of birth control throughout the trial and for 4 weeks after last dose of trial drug as defined in the protocol. 4. Any new development with the participant's disease or condition or any significant laboratory test abnormality during the course of Trial HZNP-HZN-825-301 that, in the opinion of the Investigator, would potentially put the subject at unacceptable risk. 5. Pregnant or lactating women. 6. Participants will be ineligible if, in the opinion of the Investigator, they are unlikely to comply with the trial protocol or have a concomitant disease or condition that could interfere with the conduct of the trial. |
Country | Name | City | State |
---|---|---|---|
Argentina | Aprillus Asistencia e Investigacion de Arcis Salud SRL | Ciudad Autónoma de Buenos Aires | |
Argentina | Framingham Centro Médico | La Plata | Buenos Aires |
Argentina | I.R. Medical Center - Hospital de Dia | Mendoza | |
Argentina | Centro de Investigaciones Reumatológicas | San Miguel De Tucumán | Tucumán |
Argentina | Clínica Mayo de U.M.C.B. S.R.L | San Miguel De Tucumán | Tucumán |
Austria | Medizinische Universität Graz-Auenbruggerplatz 52 | Graz | Steiermark |
France | CHU de Bordeaux - Hôpital Pellegrin | Bordeaux | Gironde |
France | AP-HP - Hôpital Cochin - Port-Royal, site Cochin | Paris | |
Germany | Charité - Universitätsmedizin Berlin | Berlin | |
Germany | Universitatsklinikum Erlangen-Universitätsstr. 21-23 | Erlangen | Bayern |
Germany | Universitätsklinikum Würzburg | Würzburg | Bayern |
Greece | General Hospital of Thessaloniki ''Hippokratio'' | Thessaloniki | |
Israel | Rambam Health Care Campus - PPDS | Haifa | |
Japan | Juntendo University Hospital | Bunkyo-Ku | Tokyo |
Japan | Nippon Medical School Hospital | Bunkyo-Ku | Tokyo |
Japan | Saitama Medical University Hospital | Iruma-Gun | Saitama |
Japan | Nagasaki University Hospital | Nagasaki-Shi | Nagasaki |
Japan | Sapporo Medical University Hospital | Sapporo | Hokkaidô |
Japan | Hokkaido University Hospital | Sapporo-Shi | Hokkaidô |
Korea, Republic of | Chonnam National University Hospital | Gwangju | Gwangju Gwang'yeogsi |
Korea, Republic of | Gangnam Severance Hospital, Yonsei University Health System | Seoul | |
Korea, Republic of | Hanyang University Seoul Hospital | Seoul | |
Mexico | Centro Integral Reumatologia SA de CV | Americana | Jalisco |
Mexico | Centro de Estudios de Investigacion Basica Y Clinica SC | Guadalajara | Jalisco |
Mexico | Clinica de Investigacion en Reumatologia y Obesidad | Guadalajara | |
Mexico | CITER, Centro de Investigacion y Tratamiento de las Enfermedades Reumaticas SA de CV | Mexico | Distrito Federal |
Mexico | Centro de Investigación y Tratamiento Reumatológico S.C | San Miguel Chapultepec I Sección | |
Poland | Twoja Przychodnia NCM | Nowa Sól | Lubuskie |
Poland | Medicover Integrated Clinical Services sp. z o.o - PPDS | Warszawa | Mazowieckie |
Spain | Hospital General Universitario Gregorio Marañon | Madrid | |
Spain | Hospital Universitario Doctor Peset | Valencia | |
United Kingdom | Royal Free Hospital | London | London, City Of |
United States | Boston University School Of Medicine | Boston | Massachusetts |
United States | Medical University of South Carolina (MUSC) - PPDS | Charleston | South Carolina |
United States | Duke University Medical Center | Durham | North Carolina |
United States | UT Physicians Rheumatology | Houston | Texas |
United States | UCLA Medical Center | Los Angeles | California |
United States | DelRicht Clinical Research, LLC - Internal - Covington - PPDS | New Orleans | Louisiana |
United States | IRIS Research and Development LLC | Plantation | Florida |
United States | Mayo Clinic - Cancer Center - Rochester - PPDS | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Amgen |
United States, Argentina, Austria, France, Germany, Greece, Israel, Japan, Korea, Republic of, Mexico, Poland, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from trial baseline, defined as the latest measurement prior to the first dose of HZN-825 in FVC % predicted | As measured by a pulmonary function test called a spirometry. | Baseline to Week 52 | |
Primary | Change from HZN-825 Baseline, defined as the latest measurement prior to the first dose of HZN-825 in either trial HZNP-HZN-825-301 or this extension trial in FVC % predicted | As measured by a pulmonary function test called a spirometry. | Baseline to Week 52 | |
Primary | Incidence of treatment emergent adverse events (TEAEs) | Day 1 to Week 56 | ||
Primary | Incidence of adverse events of special interest (AESI) orthostatic hypotension | Day 1 to Week 52 | ||
Primary | Incidence and frequency of use of concomitant medication | Day 1 to Week 56 | ||
Primary | Change from trial baseline in vital signs as reported as TEAEs | Day 1 to Week 56 | ||
Primary | Change from HZN-825 baseline in vital signs as reported as TEAEs | Day 1 to Week 56 | ||
Primary | Change from trial baseline in abnormal and clinically significant 12-lead electrocardiogram (ECG) measurements. | Clinically significant changes in ECGs is defined as any clinical significant difference in heart rate, RR interval, PR interval, QRS, and QT interval corrected using Fridericia's formula (QTcF). | Baseline to Week 52 | |
Primary | Change from HZN-825 trial baseline in abnormal and clinically significant 12-lead ECG measurements. | Clinically significant changes in ECGs is defined as any clinical significant difference in heart rate, RR interval, PR interval, QRS, and QT interval corrected using Fridericia's formula (QTcF). | Baseline to Week 52 | |
Primary | Change from trial baseline in abnormal laboratory test results | Clinically significant lab values in serum chemistry, hematology, lipids, coagulation tests and urinalyses will be assessed (including Grade 3 or higher per common terminology criteria for adverse events) | Day 1 to Week 56 | |
Primary | Change from HZN-825 baseline in abnormal laboratory test results | Clinically significant lab values in serum chemistry, hematology, lipids, coagulation tests and urinalyses will be assessed (including Grade 3 or higher per common terminology criteria for adverse events) | Day 1 to Week 56 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02161406 -
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Completed |
NCT03222492 -
Brentuximab Vedotin for Systemic Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT04137224 -
Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
|
Phase 2 | |
Not yet recruiting |
NCT04986605 -
Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Completed |
NCT02503644 -
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Recruiting |
NCT04781543 -
A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Withdrawn |
NCT05098145 -
A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis
|
Phase 1/Phase 2 | |
Terminated |
NCT04478994 -
A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1 | |
Completed |
NCT03198689 -
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Terminated |
NCT04680975 -
Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Completed |
NCT00433186 -
Mycophenolate Mofetil in Systemic Sclerosis
|
Phase 1 | |
Terminated |
NCT03919799 -
KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Not yet recruiting |
NCT06152172 -
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
|
Phase 1 | |
Suspended |
NCT04166552 -
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Not yet recruiting |
NCT06375005 -
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
|
Phase 2 | |
Recruiting |
NCT05270668 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
|
Phase 2 | |
Recruiting |
NCT05168215 -
Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.
|
||
Completed |
NCT04440592 -
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Recruiting |
NCT05149768 -
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
|
Phase 2 | |
Withdrawn |
NCT04138485 -
Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
|
Phase 2 |